Apixaban

Preventing a first clotting event with aspirin may be the only truly effective treatment option in antiphospholipid syndrome, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

Among older adults with atrial fibrillation, apixaban was linked to lower rates of adverse events across all frailty levels compared with warfarin, a retrospective observational study showed.

The ACTIV-4B trial evaluating antithrombotic therapy in patients with symptomatic COVID-19 has been stopped early due to low event rates, Brigham and Women’s Hospital announced.

Patients with cancer have a five- to sevenfold increased risk for venous thromboembolism compared with patients without cancer, and chemotherapy increases the risk by 6.5-fold.

Apixaban reduced valve thrombosis at 90 days after transcatheter aortic valve replacement, but there was no difference in ischemic outcomes at 1 year vs. standard care, according to data from the ATLANTIS 4D-CT substudy.

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of indication for oral anticoagulation.

For patients with non-valvular atrial fibrillation, study results showed treatment with apixaban was associated with a lower risk for chronic kidney disease progression compared with warfarin.